Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors

European Journal of Radiology

Volumn 82, Issue 10, 2013, Pages

  Denecke, Timm ^a   Baur, Alexander D J ^a   Ihm, Claudia ^a   Steffen, Ingo G ^a   Tischer, Elisabeth ^a   Arsenic, Ruza ^a   Pascher, Andreas ^a   Wiedenmann, Bertram ^a   Pavel, Marianne ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Liver; Metastases; Neuroendocrine tumors; Prognosis; Staging

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; EVALUATION STUDY; FEMALE; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT SELECTION; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; VERY ELDERLY;

LIVER; METASTASES; NEUROENDOCRINE TUMORS; PROGNOSIS; STAGING;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893668051     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2013.06.017     Document Type: Article

References (22)

1. Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban H, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC; 2010. p. 13-4.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. Journal of Clinical Oncology 2008;26(18):3063-72.
3. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer 2005;12(4):1083-92.
4. Pavel M, Baudin E, Couvelard A, et al. Barcelona Consensus Conference participants, ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95(2):157-76.
5. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology & Therapeutics 2010;31(January (2)):169-88.
6. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocrine-Related Cancer 2006;13(December (4)):1213-21.
7. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. Journal of Clinical Oncology 2009;27(October (28)):4656-63.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92(February (3)):205-16.
9. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Modern Pathology 2010;23(June (6)):824-33.
10. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. Journal of Endocrinology 2003;177(May (2)):337-41.
11. Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR American Journal of Roentgenology 2003;180(January (1)):121-8.
12. Procacci C, Carbognin G, Accordini S, et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. European Radiology 2001;11(7):1175-83.
13. Rodallec M, Vilgrain V, Zins M, Couvelard A, Ruszniewski P, Menu Y. Helical CT of pancreatic endocrine tumors. Journal of Computer Assisted Tomography 2002;26(September-October (5)):728-33.
14. Rodallec M, Vilgrain V, Couvelard A, et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 2006;6(1/2):77-85.
15. dassignies G, Couvelard A, Bahrami S, et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2009;250(February (2)):407-16.
16. Perren A, Roth J, Muletta-Feurer S, et al. Clonal analysis of sporadic pancreatic endocrine tumours. Journal of Pathology 1998;186(December (4)):363-71.
17. Durante C, Boukheris H, Dromain C, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocrine-Related Cancer 2009;16(June (2)):585-97.
18. Hentic O, Couvelard A, Rebours V, et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with hepatic metastases of digestive endocrine carcinomas. Endocrine-Related Cancer 2010;18(December (1)):51-9.
19. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 1997;8(July (7)):685-90.
20. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clinical Gastroenterology and Hepatology 2008;6(July (7)):820-7.
21. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology & Metabolism 2011;96(December (12)):3741-9.
22. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U. Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90(2):167-83.